Products
Nerve cells
Human iPSC-derived Parkinson's disease model in excitatory neurons for pre-clinical drug discovery
ICC showing that ioGlutamatergic Neurons PRKN R275W/R275W express pan neuronal markers
Incucyte imaging of ioGlutamatergic Neurons PRKN R275W/WT over 11 days, showing the cells form structural neuronal networks
RT-qPCR of ioGlutamatergic Neurons PRKN R275W hom showing expression of pan neuronal and glutamatergic markers
RT-qPCR analysis demonstrates expression of the PRKN gene in wild type neurons and PRKN R275W/R275W neurons
Commercially available neurons with minimum seeding density
Human iPSC-derived Parkinson's disease model in excitatory neurons for pre-clinical drug discovery
ICC showing that ioGlutamatergic Neurons PRKN R275W/R275W express pan neuronal markers
Incucyte imaging of ioGlutamatergic Neurons PRKN R275W/WT over 11 days, showing the cells form structural neuronal networks
RT-qPCR of ioGlutamatergic Neurons PRKN R275W hom showing expression of pan neuronal and glutamatergic markers
RT-qPCR analysis demonstrates expression of the PRKN gene in wild type neurons and PRKN R275W/R275W neurons
Commercially available neurons with minimum seeding density

cat no | io1020

ioGlutamatergic Neurons PRKN R275W/R275W

Human iPSC-derived Parkinson's disease model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • In vitro cell model engineered to carry a mutation in PRKN for Parkinson's disease research

  • Consistent, functional excitatory neurons that form neuronal networks within days

Place your order

Add to basket: 

Request a quote
Human iPSC-derived Parkinson's disease model in excitatory neurons for pre-clinical drug discovery

Human iPSC-derived Parkinson's disease model

ICC showing that ioGlutamatergic Neurons PRKN R275W/R275W express pan neuronal markers

ioGlutamatergic Neurons PRKN R275W/R275W express neuron-specific markers comparably to the wild-type control

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PRKN R275W/R275W compared to the genetically matched control. 100X magnification.

Incucyte imaging of ioGlutamatergic Neurons PRKN R275W/WT over 11 days, showing the cells form structural neuronal networks

ioGlutamatergic Neurons PRKN R275W/R275W form structural neuronal networks by day 11

ioGlutamatergic Neurons PRKN R275W/R275W mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, when compared to the wild-type control. Day 1 to 11 post thawing; 100X magnification.

RT-qPCR of ioGlutamatergic Neurons PRKN R275W hom showing expression of pan neuronal and glutamatergic markers

ioGlutamatergic Neurons PRKN R275W/R275W demonstrate gene expression of neuronal and glutamatergic-specific markers following deterministic programming

Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/R275W and the wild-type control (WT) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

RT-qPCR analysis demonstrates expression of the PRKN gene in wild type neurons and PRKN R275W/R275W neurons

Disease-related PRKN is expressed in ioGlutamatergic Neurons PRKN R275W/R275W following deterministic programming

RT-qPCR analysis demonstrates expression of the PRKN gene in both wild type ioGlutamatergic Neurons (WT) and ioGlutamatergic Neurons PRKN R275W/R275W at day 11 post revival. Data normalised to HMBS, n=2 replicates.

Commercially available neurons with minimum seeding density

Industry leading seeding density

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.

Human iPSC-derived Parkinson's disease model

ioGlutamatergic Neurons PRKN R275W/R275W are opti‑ox deterministically programmed excitatory neurons carrying a genetically engineered homozygous mutation in the PRKN gene encoding the Parkin protein. These cells offer a rapidly maturing, disease relevant and isogenic system for investigating the molecular and cellular significance of a homozygous R275W mutation in Parkinson’s disease.

This disease model is part of a Parkinson's disease panel of physiologically relevant human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. Additional mutations in the PD panel include a heterozygous PRKN R275W mutation, homozygous and heterozygous PINK1 Q456X, SNCA A53T and GBA mutations. All can be used alongside their genetically matched control, ioGlutamatergic Neurons.

Benchtop benefits

comparison_0

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of homozygous expression of mutant Parkin protein on disease.

scalable_0

Scalable

With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.

quick_0

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Cells arrive ready to plate


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons PRKN R275W/R275W are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male, age 55-60 years old (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 106 viable cells, Evaluation pack*: 3 small vials of >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm2

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Homozygous R275W missense mutation in the PRKN gene

Applications

Parkinson's disease research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

* Evaluation packs are intended for first-time users, or for existing users testing a new cell type or derivative. A user can request multiple evaluation packs as long as each one is for a different product, with only one pack allowed per product.
Technical data

Highly characterised and defined

ioGlutamatergic Neurons PRKN R275W/R275W express neuron-specific markers comparably to the wild-type control

ICC showing that ioGlutamatergic Neurons PRKN R275W/R275W express pan neuronal markers

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PRKN R275W/R275W compared to the genetically matched control. 100X magnification.

ioGlutamatergic Neurons PRKN R275W/R275W form structural neuronal networks by day 11

Incucyte imaging of ioGlutamatergic Neurons PRKN R275W/WT over 11 days, showing the cells form structural neuronal networks

ioGlutamatergic Neurons PRKN R275W/R275W mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, when compared to the wild-type control. Day 1 to 11 post thawing; 100X magnification.

ioGlutamatergic Neurons PRKN R275W/R275W demonstrate gene expression of neuronal and glutamatergic-specific markers following deterministic programming

RT-qPCR of ioGlutamatergic Neurons PRKN R275W hom showing expression of pan neuronal and glutamatergic markers

Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/R275W and the wild-type control (WT) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Disease-related PRKN is expressed in ioGlutamatergic Neurons PRKN R275W/R275W following deterministic programming

ioGlutamatergic_neurons-PRKN-R275W-R275W-rt-qPCR-PRKN2

RT-qPCR analysis demonstrates expression of the PRKN gene in both wild type ioGlutamatergic Neurons (WT) and ioGlutamatergic Neurons PRKN R275W/R275W at day 11 post revival. Data normalised to HMBS, n=2 replicates.

Industry leading seeding density

ioGlutamatergic_Neurons_seeding_density_small_96_384

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

How to culture ioGlutamatergic Neurons

 

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

Product resources

Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons Case study
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons

Professor Deepak Srivastava

Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders

King’s College London 

Download
ioGlutamatergic Neurons Brochure
ioGlutamatergic Neurons

bit.bio

Download
High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery Poster
High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery

Lachize, et al

Courtesy of Charles River Laboratories

2020

View poster
Rapid and consistent generation of functional microglia from reprogrammed hiPSCs to study neurodegeneration and neuroinflammation Poster
Rapid and consistent generation of functional microglia from reprogrammed hiPSCs to study neurodegeneration and neuroinflammation

Raman, et al

bit.bio

2022

View poster
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease Poster
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease

Smith, et al. 

bit.bio

2024

View poster
Alzheimer’s disease models in iPSC-derived glutamatergic neurons show increased secretion of pathogenic amyloid beta peptides Poster
Alzheimer’s disease models in iPSC-derived glutamatergic neurons show increased secretion of pathogenic amyloid beta peptides

Veteleanu et al.

bit.bio

2025

View poster
Amyloid-beta induces toxicity and cell death in human iPSC-derived neurons: alzheimer disease in vitro model Poster
Amyloid-beta induces toxicity and cell death in human iPSC-derived neurons: alzheimer disease in vitro model

Bsibsi et al.

Courtesy of Charles River Laboratories

2024

View poster

Cell culture hacks | human iPSC-derived glutamatergic neurons 

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

Read the blog
bit.bio_3x2_ioGlutamatergic Neurons_MAP2_Hoescht_x20_hi.res (1)

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

Discover ioWild Type cells
bitbio-vials-Wild_and_Disease-staggered-2500px_wide

ioCells catalogue

Human iPSC-derived cells

powered by opti-ox

Consistent. Defined. Scalable.

View all products
bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664